

Session VII – TME Diagnostics – Moderation: Munir Ghesani

March 23, 2024 | SAT | 15:30 – 16:20

Introduction: Odile Jaume, CEO ICPO Foundation




March 22-24, 2024
7th Theranostics World Congress
Santiago, Chile

HOME INFORMATION PROGRAM REGISTRATION ABSTRACTS

The banner features a green globe with a network of white dots and lines, a photograph of the Santiago skyline with snow-capped mountains in the background, and a navigation bar with links: HOME, INFORMATION, PROGRAM, REGISTRATION, ABSTRACTS.

- **Pieter van der Veken** (University of Antwerp, Belgium) DRUGLIKE, I8F-LABELED PET TRACERS TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP)
- **Frederik Giesel** (Heinrich Heine University Düsseldorf, Germany) virtual OVERVIEW OF TODAY'S CLINICAL APPLICATIONS AND PERSPECTIVES
- **Sherly Mosessian** (Sofie Bioscience, USA) & Paul Evans (GE, USA) FAPI – ADVANCEMENTS IN DIAGNOSTICS
- **Tadashi Watabe** (Osaka University, Japan) – FAPI DIAGNOSTICS – CRITICAL VIEW ON CLINICAL DEVELOPMENT)

Publications on FAP and PET imaging



ClinicalTrials.gov

[Find Studies](#) ▾ [Study Basics](#) ▾ [Submit Studies](#) ▾ [Data and API](#) ▾ [Policy](#) ▾ [About](#) ▾

Focus Your Search (all filters optional)

Condition/disease ⓘ

Other terms ⓘ

Intervention/treatment ⓘ

Location

Search by address, city, state, or country and select from the dropdown list

Search

Search for:

FAP


FAPI

Fibroblast Activation Protein


Filter for Diagnostic use only

Search conducted on March 4, 2024

FAPI tracers comprise the largest number of clinical studies





Growth in FAP diagnostic clinical trials



The most advanced tracers: [⁶⁸Ga]FAPI-46 and [¹⁸F]FAPI-74

Clinical Phases of FAP diagnostics





[⁶⁸Ga]FAPI-46

- Phase 2 in patients with Pancreatic Ductal Adenocarcinoma (PDAC)



4 sites activated: (Study activated May 2022)

- NYU Langone**
- Mayo Clinic**
- UCLA**
- BAMF Health**



68 Minutes



60 subjects planned

- 50 patients imaged (minimum one FAPI image)



[¹⁸F]FAPI-74

- Phase 2 in patients with GI Cancers: hepatocellular carcinoma, gastric cancer, colorectal and pancreatic cancer

5 sites selected: (Study activated May 2023)

- MGH**
- MSKCC**
- BAMF**
- Northwell**
- UCLA: Pending activation end of April 2024

110 Minutes

80 subjects planned

- 35 patients imaged

FAP Diagnostic

Stand-alone diagnostic

Oncology

Non-oncology

Companion diagnostic

RLT

Non-RLT

Oncology

Oncology

Non-oncology


FAPI Global Outreach Program

Current State

- 39 Countries
- 265 research studies (80 single study sites, 62 multi study sites)
- Studies include: Chemistry, pre-clinical, clinical, oncology and non-oncology
- 150 unique institutions
- Compounds: [^{18}F]-FAPI-74 and [^{68}Ga]-FAPI-46




Country breakdown of academic studies



5078 subjects planned

1782 subjects imaged



Why FAPI Global Outreach Program?

Primary Objective:

1. **Access:** Provide academic institutions access to FAPI for investigator-initiated studies to advance their and SOFIE/GEHC's research interests.
2. **Learn:** For SOFIE/GEHC to learn through this program the utility of FAPI in various indications.
3. **Data:** Identify key partners/data in support of approvals in key indications.

What we do:

Gain access to GMP grade precursor and reference standard in support of investigator-initiated trial

Technical manufacturing assistance to get the sites started

Cross Reference to SOFIE/GEHC IND(s) or IND content to pursue investigator-initiated trial

Allows sites to expand their research program and grant opportunities

Expansion of FAPI manufacturing across SOFIE Radiopharmacy Network



Our Pipeline

With over 50 years of passion and dedication for the future of PET, we have taken bold steps to advance the development of next generation radiopharmaceuticals.

[VIEW PIPELINE](#)



Partnership

We offer a range of contract manufacturing services to meet your clinical needs through our network and new Theranostics Center of Excellence.

[VIEW SERVICES](#)



PET Education

We have created a multifaceted approach designed to strengthen the quality of PET programs in your practice and deliver enhanced care to your patients.

[LEARN MORE](#)



Our Network

We have 14 network sites committed to on-time delivery of radiopharmaceuticals to meet our clients' need in diagnosing and treating critical illnesses every day.

[FIND A PHARMACY](#)

Active

Totowa, NJ

Gilroy, CA (End of April 2024)

Upcoming 2024 and 2025

Sanford, FL

Cleveland, OH

Romeoville, IL

Dallas, TX